Dallas, Texas--(Newsfile Corp. - September 30, 2022) - Bio-Path Holdings, Inc. BPTH: The full report can be accessed by clicking on the following link: https://stonegateinc.com/reports/BPTH_Q2FY22.pdf
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Bio-Path's pipeline continues to expand with new cancer indications
- Bio-Pathhas completed Phase 1 clinical trials for its lead candidate prexigebersen for AML and other blood cancers
- The Company most recently reported that cash on hand as of 6/30/22 is sufficient to fund operations according to plan for at the next 12 months
Click image above to view full announcement.
About Stonegate Capital Partners
Stonegate Capital Partners is a Dallas-based corporate advisory firm dedicated to serving the specialized needs of small-cap public companies. Since our inception, our mission has been to find innovative, undervalued public companies for our network of leading institutional investors who seek high-quality investment opportunities.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/139051
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.